Microbot Medical (NASDAQ:MBOT) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Microbot Medical (NASDAQ:MBOT) from a hold rating to a sell rating in a report issued on Thursday, Zacks.com reports.

According to Zacks, “Microbot Medical Inc. is engaged in the research, design, development and commercialization of micro-robotics assisted medical technologies. Its product candidate includes the Self Cleaning Shunt for the treatment of hydrocephalus and Normal Pressure Hydrocephalus and TipCAT, a self-propelling, semi-disposable endoscope which is being developed initially for use in colonoscopy procedures. Microbot Medical Inc., formerly known as Stemcells, Inc., is headquartered in Hingham, MA. “

A number of other analysts have also recently issued reports on MBOT. HC Wainwright reiterated a buy rating and set a $10.00 target price on shares of Microbot Medical in a report on Wednesday, September 11th. ValuEngine cut Microbot Medical from a buy rating to a hold rating in a report on Wednesday, October 30th.

MBOT traded down $0.05 during midday trading on Thursday, hitting $4.94. The company’s stock had a trading volume of 476 shares, compared to its average volume of 614,291. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.02. Microbot Medical has a 52-week low of $1.38 and a 52-week high of $19.40. The firm has a market cap of $21.41 million, a P/E ratio of -2.05 and a beta of 5.00. The firm has a 50-day moving average price of $5.43 and a two-hundred day moving average price of $5.88.

Microbot Medical (NASDAQ:MBOT) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.09. On average, equities analysts expect that Microbot Medical will post -1.46 EPS for the current year.

Several large investors have recently modified their holdings of MBOT. Morgan Stanley grew its holdings in shares of Microbot Medical by 77.0% during the 2nd quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 2,748 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Microbot Medical during the 2nd quarter worth about $45,000. BlackRock Inc. lifted its position in Microbot Medical by 5.7% during the 2nd quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock worth $945,000 after acquiring an additional 9,906 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Microbot Medical by 5.5% during the 2nd quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock worth $1,065,000 after acquiring an additional 10,838 shares in the last quarter. Institutional investors and hedge funds own 14.84% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.

See Also: What are the risks of holding treasury bonds?

Get a free copy of the Zacks research report on Microbot Medical (MBOT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.